Pourmir, I.; Elaidi, R.; Maaradji, Z.; De Saint Basile, H.; Ung, M.; Ismaili, M.; Fournier, L.; Rance, B.; Gibault, L.; Ben Dhiab, R.;
et al. Longitudinal Study of Advanced Non-Small Cell Lung Cancer with Initial Durable Clinical Benefit to Immunotherapy: Strategies for Anti-PD-1/PD-L1 Continuation beyond Progression. Cancers 2023, 15, 5587.
https://doi.org/10.3390/cancers15235587
AMA Style
Pourmir I, Elaidi R, Maaradji Z, De Saint Basile H, Ung M, Ismaili M, Fournier L, Rance B, Gibault L, Ben Dhiab R,
et al. Longitudinal Study of Advanced Non-Small Cell Lung Cancer with Initial Durable Clinical Benefit to Immunotherapy: Strategies for Anti-PD-1/PD-L1 Continuation beyond Progression. Cancers. 2023; 15(23):5587.
https://doi.org/10.3390/cancers15235587
Chicago/Turabian Style
Pourmir, Ivan, Reza Elaidi, Zineb Maaradji, Hortense De Saint Basile, Monivann Ung, Mohammed Ismaili, Laure Fournier, Bastien Rance, Laure Gibault, Rym Ben Dhiab,
and et al. 2023. "Longitudinal Study of Advanced Non-Small Cell Lung Cancer with Initial Durable Clinical Benefit to Immunotherapy: Strategies for Anti-PD-1/PD-L1 Continuation beyond Progression" Cancers 15, no. 23: 5587.
https://doi.org/10.3390/cancers15235587
APA Style
Pourmir, I., Elaidi, R., Maaradji, Z., De Saint Basile, H., Ung, M., Ismaili, M., Fournier, L., Rance, B., Gibault, L., Ben Dhiab, R., Gazeau, B., & Fabre, E.
(2023). Longitudinal Study of Advanced Non-Small Cell Lung Cancer with Initial Durable Clinical Benefit to Immunotherapy: Strategies for Anti-PD-1/PD-L1 Continuation beyond Progression. Cancers, 15(23), 5587.
https://doi.org/10.3390/cancers15235587
